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Background: The aims of this study were to compare the overall regulatory review
timelines achieved by the South African Health Products Regulatory Authority (SAHPRA) in
2020 to the timelines historically achieved by the Medicines Control Council (MCC). This
study also aimed to evaluate the regulatory review processes and the good review
practices that have been implemented by SAHPRA to support the assessment of new
chemical entities and generic product applications for market authorization in the
business-as-usual and backlog process streams.
Methods: A questionnaire was completed and verified by SAHPRA to describe the
structure of the organization, the resources available, the process for regulatory review of
new chemical entities and generic products and the level of implementation of good review
practices and regulatory decision-making practices for market authorization. Data were
collected and analyzed on the overall approval timelines for new chemical entities and
generic products registered by SAHPRA in 2020 in the business-as-usual and backlog
process streams.
Results: A full, independent scientific review was conducted for all new chemical entities
and generic product applications in the business-as-usual stream. Facilitated regulatory
pathways were introduced for the review of new chemical entities and generic products in
the backlog stream. As a result, the timelines for approval of applications in the backlog
stream were 68% quicker for both new chemical entities and generics, using facilitated
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Conclusion: The comparisons made through this study provided insight into the
improvements that have been made through the establishment of SAHPRA and the
transition in 2018 from the MCC. The re-engineered processes that have been developed
and implemented by SAHPRA to address the backlog in the review of the applications for
market authorization have demonstrated a decrease in the overall median approval times.
The expansion of these processes into the routine review of medical products will
contribute to the enhanced regulatory performance of SAHPRA and patients’ access
to new medicines.
Keywords: south african regulatory review times, south african health products regulatory authority, backlog, good
review practices, regulatory performance
INTRODUCTION
The South African Health Products Regulatory Authority
(SAHPRA) is the national regulatory authority (NRA) of
South Africa, mandated through the Medicines and Related
Substances Control Act, 1965 (Act 101 of 1965) to ensure the
safety, quality and efficacy of medical products (Republic of South
Africa, 2017). In 2017, amendments to Act 101 of 1965, set forth a
significant change in the legislature and the organizational
structure of the South African NRA and triggered the
establishment of SAHPRA to replace the former medicine
regulatory authority the Medicines Control Council (MCC)
(Keyter et al., 2018a). Historically the MCC had a reputation
for robust evidentiary assessments of medical products for market
authorization, but was affected by operational challenges and
resource constraints that resulted in extended timelines for
regulatory review. Efforts were made to reorganize processes
and improve the capacity of assessment teams and pilot
programs endeavoured to address these issues, but a
significant backlog developed, and patients’ access to
medicines was delayed.
The SAHPRA has quantified the backlog (BL) and firm targets
have been set for its clearance. Inherited processes and practices
have been reassessed and pilot projects have been initiated to
support new methodologies required to achieve this goal. These
include enhanced document management systems, reformed
work streams with resources to support this, revised
performance contract models, project management tools and
the application of facilitated regulatory pathways (FRPs).
Applications received by the MCC and/or SAHPRA prior to
February 1, 2018 are considered to be part of the BL and have
been processed as part of the pilot of the new methodologies.
Applications for market authorization that were received by
SAHPRA from February 1, 2018 are considered to be in the
“business as usual” (BAU) work stream. These applications
have been processed using the inherited regulatory review
process that was initially developed by the MCC. Keyter and
colleagues studied the regulatory review process of the MCC
and the overall approval timelines achieved, using this
process during the period 2015–2017 (Keyter et al., 2018a).
The outcomes of this study serve as a baseline for assessing
the changes that have been implemented by SAHPRA as it
moves toward enhanced regulatory responsiveness and
improved regulatory performance.
National regulatory authorities globally recognize the need to
develop and maintain effective and efficient regulatory review
processes while managing capacity constraints, legislative
limitations, advancing technologies, and large volumes of
applications for the market authorization of medical products
(Hill and Johnson, 2004; Cone and Walker, 2005; Cone and
McAuslane, 2006). Several strategies have been enlisted by NRAs
to support regulatory reform. The formal implementation of good
review practices (GRevPs) provides the fundamental foundation
for regulatory review processes and is a measure on which the
regulatory performance of the regulator may be measured. The 10
key principles of GRevPs support consistent, thorough, well-
documented, evidence-based, efficient, and well-managed
reviews (World Health Organization, 2015). NRAs may also
consider the use of FRPs such as reliance mechanisms to
conserve limited resources and avoid duplication of regulatory
effort. The application of FRPs contribute towards decreased
timelines for the evaluation of applications for market
authorization as the NRA may rely on or recognize the
regulatory decision made by a reference NRA. In this way, the
NRA does not need to conduct a full review of the data submitted
to support the application for market authorization and can
realistically achieve shorter overall approval timelines. With
the advent of SAHPRA, opportunities to re-engineer the
regulatory review process brought renewed goals for enhanced
regulatory performance (Keyter et al., 2018b).
This Study Aimed to
⁃ Evaluate the overall approval timelines for new chemical
entities (NCEs) over the period 2015–2020 wherein different
review pathways were applied;
⁃ Compare the overall regulatory review timelines achieved
by SAHPRA (2018–2020) to the timelines historically
achieved by the MCC (2015–2017);
⁃ Compare the South African regulatory review processes
that have been implemented by SAHPRA to support the
assessment of NCEs and generic product applications for
market authorization in the BAU and BL streams;
⁃ Evaluate the level of implementation of GRevPs in the
regulatory review process by SAHPRA; and
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⁃ Review the challenges and opportunities for enhancing the
regulatory performance of SAHPRA leading to decreased
overall approval timelines for NCEs and generics.
METHODS
Study Participants
This study provides a comparison of the two regulatory review
processes implemented by SAHPRA for the registration of
products in 2020. The first regulatory review process is the
one that has been applied to applications for market
authorization, received by SAHPRA prior to February 1, 2018,
which forms part of the BL stream. The second regulatory review
process is the one that has been applied to applications for market
authorization, received by SAHPRA from February 1, 2018,
which forms part of the BAU stream.
Study Tool and Data Collection Process
The Centre for Innovation in Regulatory Science (CIRS)
developed and validated the tool that was used to collect the
regulatory system information for SAHPRA (McAuslane et al.,
2009). The tool was presented as a five-part questionnaire that
was completed by SAHPRA: part 1 provided insight into the
organization and structure of SAHPRA and the available
resources; part 2 identified the regulatory review model/s
applied by SAHPRA; part 3 was used to map the regulatory
review process and the targets and milestones within the review
process that allowed for analysis of regulatory performance; part 4
identified the GRevPs that were implemented by SAHPRA to
build quality into the regulatory review process; and part 5
explored the evidence supporting the implementation of
quality decision-making practices (QDMPs) in regulatory
decision making for market authorization.
The questionnaire was completed in duplicate to reflect the
regulatory review processes that were applied by SAHPRA to
applications for market authorization within the BL and BAU
streams. The questionnaires were completed by the various
unit heads within SAHPRA and verified by the Chief
Regulatory Officer and Chief Executive Officer of
SAHPRA. Data were collected to reflect the median
regulatory review timelines for NCEs (including
biologicals) and generics from the date of receipt of the
application (prior to February 1, 2018  BL; after February
1, 2018  BAU) to the date of approval in 2020. The data were
sourced directly from the SAHPRA Units responsible for
monitoring and evaluating the regulatory performance
metrics. It should be noted that no data were available for
2019, as the agency was unable to operate during this period
due to a number of mitigating circumstances.
Models of Regulatory Review
Review Assessment Type I—Verification Model
The verification model, as defined by McAuslane and associates,
provides a mechanism for NRAs to rely on or recognize the
regulatory decision of a reference NRA (McAuslane et al., 2009).
This model promotes faster regulatory review times as the data
submitted is verified for compliance against that which was
submitted to the reference NRA. The use of the verification
model allows the NRA to avoid duplication of regulatory
effort and to conserve limited resources.
Review Assessment Type II—Abridged Review Model
McAuslane and colleagues describe the abridged review model as
a selective review of the data submitted for market authorization,
provided that the product has been registered by a reference NRA
(McAuslane et al., 2009). This type of review is often limited to an
assessment of the country-specific requirements for product
quality and the clinical data associated with the benefit-risk
assessment of the product.
Review Assessment Type III—Full Review Model
The full review model requires a full independent scientific
assessment of the data submitted for market authorization
(McAuslane et al., 2009). This review model does not require
market authorization with a reference NRA as a prerequisite.
Ethics Approval
The study has been approved by the Health, Science, Engineering
and Technology ECDA, University of Hertfordshire [Reference
Protocol number: LMS/PGR/UH/03873].
RESULTS
Comparative Assessment of Regulatory
Review Processes and Milestones
Figure 1 shows a simplified illustration comparing the SAHPRA
registration review process, milestones, and target review times
for the BAU and BL process streams. Figure 1 represents the
process for NCEs and generics that were approved in the first
review cycle and does not represent the process for applications
that were not recommended for market authorization.
The NCE and generic applications for market authorization
received prior to February 1, 2018, in the BL stream were
processed by SAHPRA using the full review model, the
abridged review model or the verification model. Registration
with at least one reference NRA was a prerequisite for the use of
the abridged review model and registration with at least two
NRAs was required for the verification model. SAHPRA required
the applicant to provide additional data to support the indications
if there were differences in the product indications between the
registrations approved by the two reference NRAs. The NCE and
generic applications for market authorization, received after
February 1, 2018 were assessed in the BAU stream, using the
full, independent, scientific review model.
Assessments of applications for market authorization were
conducted by both internal and external assessors. SAHPRA
appointed a total of 113 assessors to review applications for
market authorization, of whom 57 were allocated to review
applications for BAU only. The primary scientific assessment
was followed by a peer-review, conducted by a second assessor.
Expert committees were used in the review process in an advisory
capacity. The clinical and quality expert committees were
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engaged in the BAU review process while only the clinical expert
committee participated in the BL review.
Products requiring priority review were “fast-tracked”
provided that the priority designation was confirmed at
pre-registration through identification by the National
Department of Health, to meet an unmet public health need.
Products eligible for priority review were usually already
registered in another jurisdiction. A copy of the registration
certificate was required, although a Certificate of
Pharmaceutical Product was not. The data requirements and
scientific assessment criteria for priority products were the same
as those for other products, but priority review products were not
placed in the queue for review and were allocated immediately to
an assessor. The target timeline for the review of priority products
was 350 calendar days; however, there were no products fast
tracked for priority review in the BAU or the BL streams in the
data reviewed in this study.
Data Requirements
The SAHPRA placed reliance on and/or recognized the
regulatory decisions of reference NRAs/organizations/
collaborative initiatives to inform their own regulatory
decision making. The SAHPRA considered the following
NRAs as reference agencies: United States Food and Drug
Administration (USFDA), the European Medicines Agency
(EMA), individual European Union Member States, the
Japanese Pharmaceuticals and Medical Devices Agency
(PMDA), Health Canada, Swissmedic, the Medicines and
Healthcare products Regulatory Agency (MHRA) of the
United Kingdom and the Australian Therapeutic Goods
Administration (TGA). The SAHPRA also relied on and/or
recognized product pre-qualifications performed by the World
Health Organization (WHO) and the regulatory decisions made
through the Zazibona Collaborative Medicines Registration
pathway. The SAHPRA applied reliance pathways in the
review of products in the BL stream but did not apply a
reliance strategy in the assessment of products in the BAU
stream. SAHPRA did not have a formal pre-application
procedure in place and there was no requirement for the
applicant to submit a notification of intent to make
application for market authorization while there was clear
published data requirements for the assessment of applications
for market authorization using the verification, abridged, and full
review models (Table 1).
SAHPRA required the submission of the full common
technical document (CTD) to support the application for
FIGURE 1 | Registration process map for the SAHPRA backlog (BL) stream and business-as-usual (BAU) stream. *No clock stop indicates that the sponsor’s
response time is included in the overall review time
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market authorization, irrespective of the model of assessment
applied. The extent of the scientific assessment performed by
SAHPRA differed based on the model of assessment applied.
For the verification and abridged review models, SAHPRA
required the applicant to request the reference NRA to give
SAHPRA permission to access the un-redacted assessment
report of the registered product. If the un-redacted report
was not available, SAHPRA would obtain the redacted
assessment report from the public domain. The redacted
report would be accepted if the report contained sufficient
scientific data, such as the inclusion of information
pertaining to the active pharmaceutical ingredient (API), to
inform regulatory decision making. The abridged review model
was applied with a focus on the use of the product under local
conditions. The clinical opinion took account of the national
disease patterns, ethnic factors, unmet medical needs, and
differences in medical practice and culture. The full review
model was further stratified by SAHPRA as either A)
whereby a full review was performed and information on
prior registration of the product in another jurisdiction was a
prerequisite for market authorization; or B) whereby a full,
detailed, independent review was performed.
Target and Approval Times
The transition of the MCC to SAHPRA brought with it an
opportunity to re-engineer the South African regulatory review
process. The regulatory review processes implemented by SAHPRA
for the BAU and BL streams and the associated milestones and
timelines are depicted in Figure 1. Themilestones within the review
process were previously defined (Keyter et al., 2019a). SAHPRA
target timelines for the milestones within the BAU and BL
regulatory review processes have been compared against the
previous MCC target timelines (Table 2). SAHPRA target
timelines for validation of the application (35 calendar days)
exceeded the MCC target timeline (15 calendar days) and the
target timeline for validation of BL applications (35 calendar
days) was longer than for BAU applications (18 calendar days).
There was no target timeline for scientific assessment for
applications in the BAU stream. The target scientific assessment
time for applications in the BL (150 calendar days) was longer than
TABLE 1 | Data requirements for the review models and extent of the scientific assessment.
Type of review model Verification model Abridged review model Full review model
NCEs + generics in BAU 7 7 ✓
NCEs + generics in BL ✓ ✓ ✓
ADDITIONAL INFORMATION OBTAINED
Registration by reference NRA ✓a ✓b 7
Certificate of pharmaceutical product ✓ 7 7c
Similarity to registered product ✓d ✓d 7
EXTENT OF SCIENTIFIC ASSESSMENT
Quality data ✓e ✓e ✓f
Non-clinical data ✓g ✓g ✓f
Clinical data ✓g ✓g ✓f
Adapted from Keyter et al., 2018a.
BAU, business as usual; BL, backlog; NRA, national regulatory authority; NCE new chemical entity.
aRequires registration by at least two reference NRAs.
bRequires registration by at least one reference NRA.
cRequired if available at the time of submission.
dThe dosage form, strength, ingredients, indications, and dosage, warnings and precautions, product label and product name must be identical to the product registered by the
reference NRA.
eA checklist review for completeness of data is conducted.
fA full review is conducted.
gA selective review in detail is conducted.
TABLE 2 | Target timelines for SAHPRA review process compared with previous MCC timelines.
Process MCCa SAHPRA BAU SAHPRA BL
Validation 15 calendar days 18 calendar days 35 calendar days
Scientific assessment 90 calendar days No target ∼150 calendar days
Sponsor response time 180 calendar days 42 calendar days 30 calendar days
Expert committee(s) 60 calendar days No target No target
Administration time 60 calendar days 14 calendar days 35 calendar days
Notification of decision 7 calendar days 10 calendar days 7 calendar days
Overall review time (fast track) 250 calendar days 350 calendar days 350 calendar days
Overall review time (NCEs) No target 590 calendar days 250 calendar days
Overall review time (generics) No target 250 calendar days 250 calendar days
aKeyter et al., 2018a.
BAU, business as usual; BL, backlog; MCC, Medicines Control Council; NCEs, new chemical entities; SAHPRA, South African Health Products Regulatory Authority.
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the MCC target timeline for scientific assessment (90 calendar
days). There were no target timelines for the expert committee
review in both the BAU and BL streams. The target timelines for the
authorization procedure decreased in comparison to the previous
MCC target timeline.
The median overall approval timeline for NCEs (783 calendar
days) decreased by 63% in 2020 compared to the highest median
overall approval timeline for NCEs (2,124 calendar days) that was
recorded in 2018 (Table 3). This was much shorter than the median
timelines for MCC over the three-year period (2015–2017).
The overall median approval timeline for both the NCEs and
generic product applications was 792 calendar days in the BAU
stream and 257 calendar days in the BL stream in 2020 (Figure 2).
The overall approval timeline for NCEs was 961 calendar days
and 303 calendar days for the BAU stream and the BL stream,
respectively. The time taken to approve NCEs using the FRPs
applied in the BL stream was 68% quicker than the time taken to
approve NCEs in the BAU stream. The overall approval timeline
for generics was 756 calendar days for the BAU stream and 246
calendar days for the BL stream. The overall approval timeline for
generics decreased by 68% in the BL stream when compared to
the timelines observed for the approval of generics in the BAU
stream.
The NCEs and generics in the BL review stream that were
approved in 2020 were processed through the full review model
TABLE 3 | Median overall approval timelines for NCEs from 2015–2020.
NRA MCCa MCCa MCCa SAHPRAa SAHPRAb SAHPRA
Year 2015 2016 2017 2018 2019 2020
Number of NCEs approved 31 33 42 15 — 155
Median overall approval timeline 1,175 1726 1,466 2,124 — 783
MCC, Medicines Control Council; NCE, new chemical entities; NRA, national regulatory authority; SAHPRA, South African Health Products Regulatory Authority.
aKeyter, et al., 2019a.
bNo data were available for 2019.
FIGURE 2 |Median overall approval times for new chemical entities and
generics processed through the BAU and BL review streams in 2020. BAU,
business as usual; BL, backlog; NCE, new chemical entity. Data are shown for
NCEs and generics that were approved in 2020 through the business as
usual and the backlog process streams. (n)  number of product applications
registered in 2020. Box: 25th and 75th percentiles. Whiskers: 5th and 95th
percentiles. Denotes median.
FIGURE 3 |Median overall approval times for new chemical entities and
generics, in the backlog review stream, processed through the full review
model, the abridged review model, and the verification model in 2020. BL,
backlog; NCE, new chemical entity. Data are shown for NCEs and
generics in the backlog process stream that were approved in 2020 using the
full, abridged and verification review models. (n1)  number of product
applications registered in 2020. Box: 25th and 75th percentiles. Whiskers: 5th
and 95th percentiles.
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and through FRPs including the abridged review model and the
verification model (Figure 3). The overall median approval
timeline for NCEs in the BL stream was 336 calendar days
using the full review model, 303 calendar days using the
abridged review model, and 236 calendar days using the
verification model. The use of FRPs demonstrated a decrease
of 10% for abridged review of NCEs and a decrease of 30% for
verification of NCEs when compared to the time taken to conduct
a full review of NCEs in the BL stream. The overall median
approval timeline for generics in the BL stream was 251 calendar
days, 261 calendar days, and 199 calendar days, using the full
review model, the abridged review model, and the verification
model, respectively. The time taken to review a generic
application in the BL stream, using the verification model was
21% less than the time taken using the full review model. An
increase of 4% was observed in the application of the abridged
review model when compared to the time taken to conduct a full
review of generics in the BL stream.
Comparative Assessment of Good Review
Practices
The status of the implementation of GRevPs by the MCC was
evaluated to determine the effectiveness of the regulatory review
TABLE 4 | Status of implementation of good review practices by SAHPRA.
Indicator MCC statusa Commentsa SAHPRA status Comments
Quality measures
Internal quality policy ✓ Planned to formally implement ✓ Implemented
Good review practice system ✓ Planned to formally implement ✓ Improvement required to support timeliness of review
Standard operating procedures (SOPs) for
guidance of assessors
✓ Planned to formally implement ✓ SOPs for all procedures in the regulatory review to be
formalized
Assessment templates ✓ Planned to formalize the use of a single,
common template
✓ Templates for clinical assessment and abridged and
verification reviews have been formally implemented
Dedicated quality department 7 Establishment of a dedicated quality
department is planned
✓ Quality manager has been appointed, team to be
recruited
Scientific committee ✓ — ✓ —
Shared and joint reviews ✓ — ✓ —
Transparency and communication parameters
Feedback to industry on submitted
dossiers
✓ — ✓ —
Details of technical staff to contact ✓ Contact details are made available on an ad-
hoc basis
✓ Contact details are made available on an ad-hoc basis
Pre-submission scientific advice to industry ✓ Meetings are held with industry on an ad-hoc
basis
✓ Pre-submission advice is provided for only biologicals
and various COVID-19 related applications
Official guidelines to assist industry ✓ — ✓ —
Industry can track progress of applications 7 Implementation of electronic document
management system is planned
✓ Tracking was implemented for applications in the backlog
and BAU process streams
Publicly available summary basis of
approval (SBA)
7 Summary is available but is currently not
published
7 ZAPAR not produced or published but planned to
implement in future
Approval times ✓ Approval times are not made available to the
public
✓ Approval times are not made available to the public
Advisory committee meeting dates ✓ — ✓ —
Approval of products ✓ — ✓ —
Continuous improvement initiatives
External quality audits ✓ External quality audits are not performed
routinely
✓ External quality audits are now in place
Internal quality audits 7 Planned ✓ Planned to be formally implemented and conducted by
the quality department
Internal tracking systems ✓ Implementation of electronic document
management system is planned
✓ Tracking implemented for applications in the backlog and
BAU process streams
Review of assessors’ feedback ✓ — ✓ —
Reviews of stakeholders’ feedback ✓ Planned to be formally and routinely reviewed ✓ Formally implemented
Training and education
International workshops/conferences ✓ — ✓ —
External courses ✓ — ✓ —
In-house courses ✓ Training program to be formalized ✓ Training program to be formalized and effectiveness of
training to be measured
On-the-job training ✓ Training program to be formalized ✓ Training program to be formalized and effectiveness of
training to be measured
External speakers invited to the authority ✓ — ✓ —
Induction training ✓ Training program to be formalized ✓ Training program to be formalized and effectiveness of
training to be measured
Sponsorship of post-graduate degrees ✓ — ✓ —
Placements and secondments in other
regulatory authorities
✓ — ✓ —
Legend Formally implemented Informally implemented Not implemented
aAdapted from Keyter et al., 2018a.
MCC, Medicines Control Council; SAHPRA, South African Health Products Regulatory Authority; SBA, Summary Basis of Approval; SOP, standard operating procedure, ZAPAR, South
African public assessment report.
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process (Keyter et al., 2018a). Since the inception of SAHPRA,
further work has been done to formalize the implementation of the
GRevPs in an effort to enhance the regulatory review process.
Table 4 provides a comparison of the implementation of the
parameters of the GRevPs that were implemented by the MCC
and the progress that has been made by SAHPRA.
Enablers and Barriers to Good Quality
Decision Making
The MCC developed a framework for regulatory decision
making based upon the formalized legislature, policies, and
guidelines. The study conducted by Keyter and colleagues did
not provide an assessment of the QDMPs considered and/or
implemented by the MCC (Keyter et al., 2018a). SAHPRA has
adopted the regulatory decision-making framework established
by the MCC; however, the process of building quality into
decision-making practices has not been formalized. The
agency assessed which of the 10 QDMPs have been
implemented (Bujar et al., 2017) and the outcome of this
process is illustrated in Figure 4.
DISCUSSION
Review Type and Process
Globally, NRAs have shifted their focus toward the enhancement
of regulatory performance and faster regulatory approval
timelines. The advent of the implementation of FRPs allows
NRAs to rely on or recognize the regulatory decisions of other
reference agencies. Making use of the abridged review model and
the verification model allows NRAs to decrease the time taken to
review an application for market authorization (Keyter et al.,
2020a). SAHPRA has introduced the use of the abridged review
and verification models to the applications in the BL stream.
Generally, the results demonstrated a decrease in the time spent
on the review of applications that were channelled through FRPs.
In this study, the time taken to perform a verification was
significantly less than the time taken to perform a full review. It is
interesting that the review time for generics that underwent the
abridged review took longer than those that underwent the full
review. It is likely that the extent of the review conducted using
the abridged review model has not been sufficiently modified to a
selective, detailed review, limited to specific parts of the submitted
CTD. It was noted that the verification model applied by
SAHPRA currently requires a specific detailed review of non-
clinical and clinical data; and that applications were routed to
ensure that the product submitted to SAHPRA was identical to
the product registered by the reference NRA/s. These practices
may have contributed to the extended validation period
(increased from 15 calendar days to 35 calendar days)
identified for products in the BL stream that were subjected to
verification and abridged review. In line with the definitions for
reviews using the verificationmodel or the abridged reviewmodel
(McAuslane et al., 2009), it would be prudent to limit reviews
using the verification model to a check for completeness of data
instead of a selective, detailed review; and accepting the signed
declaration of sameness from the applicant without conducting
an additional cross-check to confirm sameness for each part of
the CTD submitted. Routine implementation of these practices
will ensure that limited resources are conserved, that the
regulatory effort is commensurate with the level of risk of the
product, and that the assessors are able to consistently exercise
the level of restraint required for the extent of the review that is
recommended when performing a review using the verification
model or the abridged review model (Keyter et al., 2020a).
Target and Approval Times
The overall median approval timeline for medical products,
achieved by an NRA, is largely indicative of the regulatory
performance of the NRA. In order to enhance regulatory
performance, NRAs are recommended to monitor and
evaluate their regulatory performance metrics. This can be
achieved by documenting the regulatory review process,
FIGURE 4 | Status of implementation of quality decision-making practices.
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identifying the milestones within the process, and determining
the target timelines to be achieved for each activity. The review
process that had been developed and implemented by the MCC
was adopted by SAHPRA, upon its establishment as the new
South African NRA in 2018 (Keyter et al., 2019b). Data reflecting
the overall approval timelines for NCEs, achieved by the MCC
from 2015–2017 and by SAHPRA in 2018, demonstrated
extended timelines and unacceptable regulatory performance
that negatively affected patients’ access to medicines in South
Africa (Keyter et al., 2019b). The overall approval timeline for
NCEs has significantly decreased since 2018 and this result is a
testament to the positive impact of the changes that have already
been introduced by SAHPRA. The overall approval timelines for
applications in the BL are significantly less than that achieved for
the applications in the BAU stream. It is acknowledged that most
of the products approved in 2020 were part of the BAU stream;
however, the FRPs, operational processes, additional
infrastructure, and formalization of the performance contracts,
the assessment guidelines, and the templates have been pivotal in
accelerating the review of the applications in the BL stream.
Historically, the target timelines set by the MCC were not
achievable and the legislative and operational influences that
negatively affected the performance of the MCC have been
previously reported (Keyter et al., 2018b). SAHPRA has
identified target overall approval timelines for the review of
NCEs and generics in the BL and an overall target timeline for
all products in the BAU stream. The target overall approval
timelines identified for BAU (250 calendar days) are shorter than
those identified for priority-review products (350 calendar days).
Currently, the median overall approval timeline achieved by
SAHPRA for BAU is 792 calendar days, more than three
times the current target. Mature regulatory authorities such as
the TGA, Health Canada, and the HSA have set targets for NCE
approval at 305 calendar days, 355 calendar days, and 270
working days, respectively. This may indicate that the targets
that have been set by SAHPRA have been ambitious, and that if
these targets are to be formally adopted as key performance
indicators, dedicated efforts will be required to meet these goals.
Good Review Practices
NRAs are mandated to ensure the safety, quality, and efficacy of
medical products. NRAs review applications for market
authorization against scientific and evidentiary requirements to
inform regulatory decision making to approve or refuse the
registration of a product. The NRAs are required to effect
their regulatory mandate in a timely manner (World Health
Organization, 2015). They can enhance their regulatory systems
by incorporating GRevPs in routine regulatory undertakings and
ultimately improve their regulatory performance (World Health
Organization, 2014a; World Health Organization, 2015).
SAHPRA has worked diligently to formalize the
implementation of GRevPs over the last 3 years; however,
there are two areas for improvement that have been identified.
First, a key feature of the GRevPs is a well-documented and
thorough report of the scientific data assessed to support the
documented rationale for the regulatory decision. SAHPRA
should consider the implementation of the Universal Model
for Benefit-Risk Assessment (UMBRA) framework as a
template that may be used for the clinical assessment
informing the benefit-risk decision (Keyter et al., 2020b,
Walker et al., 2011; Walker et al., 2013). The UMBRA
framework has been validated and utilized by many mature
NRAs (Walker et al., 2011) and those in emerging markets
(Mashaki Ceyhan et al., 2018). Second, SAHPRA should
recognize the importance of a well-managed review as a
leading principle of GRevPs. In this regard it is expected that
a good review is supported by a fully integrated project
management process and a quality management process
underpinned by defined target timelines and achievable
performance metrics (World Health Organization, 2015). As
such, setting achievable targets and routinely measuring and
evaluating performance metrics will serve to further enhance
and continuously improve the regulatory output and
responsiveness of SAHPRA.
SAHPRA has appointed a quality manager and is in the
process of further capacitating a Quality Department. The
additional resources in the Quality Department will provide
the foundation for the codification of the internal quality
policy, the planned routine internal auditing activities, and
the sustainability of the formalized implementation of a
robust quality management system. As a result,
opportunities exist for SAHPRA to develop and implement
standard operating procedures for each of the regulatory
review processes, update templates for clinical assessment
to elucidate the benefit-risk assessment in a structured,
systematic documented way, and build QDMPs into the
review (Keyter et al., 2020b).
SAHPRA does not publish the summary basis of approval
that documents the benefit-risk decision; however, the
decision to recommend or not recommend a product for
market authorization is communicated to the applicant.
SAHPRA is considering the development and publication
of the South African public assessment report (ZAPAR) to
ensure consistency and enhance transparency in regulatory
decision making (Keyter et al., 2020b). The routine
publication of the ZAPAR may serve to promote the
position of SAHPRA as a reference NRA, whose
regulatory decisions may be relied upon or recognized by
other NRAs.
SAHPRA has recognized the importance of implementing
an electronic document management system (EDMS) that is
driven by integrated and adequate information and
communication technology infrastructure, to facilitate
effective project management and tracking of applications
for market authorization (Hill and Johnson, 2004; Keyter
et al., 2018b). The opportunity to pilot the EDMS has been
harnessed by SAHPRA in its application within the BL
process stream. The pilot implementation of the EDMS
has facilitated internal and external tracking of
documents; ultimately contributing to increased
transparency and enhanced trust from both internal and
external stakeholders.
SAHPRA has implemented several training and education
modalities (Keyter et al., 2018a); however, the formalization
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of the training programs required to support induction
training, on-the-job training, and in-house courses has not
been formally documented and encoded into organization-
wide training structures. As SAHPRA moves forward with
this activity it will be critical to incorporate a formalized,
robust mechanism to implement, evaluate, and evaluate the
effectiveness of training activities (World Health
Organization, 2018a).
Quality Decision-Making Practices
SAHPRA has adopted the historic framework for regulatory
decision-making developed by the MCC. A systematic,
structured approach to decision making is in place and the
roles and responsibilities of assessors and committee
members are well defined. A basic record trail of
decisions made is available and decisions are re-evaluated
in the event of new information becoming available.
NRAs are required to demonstrate the effective
application of QDMPs (World Health Organization,
2018a). While there is a robust policy for the management
of potential or identified conflicts of interest, SAHPRA does
not currently evaluate and document internal and external
influences and biases, as well as heuristics and uncertainties
that may exist. It is recommended that QDMPs are
evaluated using the Quality Decision Orientation Scheme
(QoDoS) (Donelan et al., 2016; Bujar et al., 2017).
Building quality into regulatory decision-making practices
would contribute towards well-documented, clear and
succinct decisions, that are consistent and transparent in
terms of the criteria for registration, that cannot be
contested, and that could potentially be relied on or
recognized by others (Keyter et al., 2020c; World Health
Organization, 2018b).
Recommendations
The historical operations of the MCC have been compared with
the processes that have been reengineered by SAHPRA to address
the applications for market authorization in the BL, as well as the
routine applications received by SAHPRA in the BAU stream.
SAHPRA has made notable strides towards achieving their goal
for enhanced regulatory performance. Many changes and
improvements have been implemented under the leadership of
the new CEO of SAHPRA and the supporting management team.
While the strengths of SAHPRA have been identified, it is
important to recognize areas for further improvements. Based
on the outcomes of this study, the following recommendations
should be considered.
⁃ Reliance strategy: Implementation of facilitated regulatory
pathways for all applications for market authorizations and
implementation of a risk-based approach to the regulatory
review to ensure that; the specific parts of the CTD to be
reviewed are identified, the extent of the review is limited
proportionately to product risk; and the application of risk-
based regulatory review practices is consistent
⁃ Benefit-risk assessment: Implementation of a benefit-risk
assessment framework such as the UMBRA in the regulatory
process
⁃ Target timelines: Establish and enforce achievable target
timelines for the regulatory review process and routinely and
accurately measure and evaluate regulatory performance
metrics
⁃ Public assessment reports: Consider the development and
publication of the ZAPAR to ensure consistency and
transparency in regulatory decision making and to
endorse the status of SAHPRA as a potential reference NRA
⁃ Quality decision-making practices: Consider the integration
of QDMPs to support consistent, evidence-based, transparent
practices that support the publication of regulatory decisions
in the public domain.
Limitations of the Study
The lack of data for the year 2019 could be considered as a
limitation of this study. The mitigating circumstances were that
the former SAHPRA premises were declared unfit as a working
environment, which necessitated a major move to new
accommodations. As a result, no products were reviewed in
that period.
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